Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone in Pediatric Relapsed/Refractory Cancer
NCT02800889Phase 1Withdrawn
- Sponsor
- CTI BioPharma Corp.
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pixantrone in lymphoma and solid tumor, sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Tolerated Dose at 28 days and Anti-tumor activity at 1 year. Planned start Oct 2016; status: withdrawn.
02
Drugs
pixantrone
03
Conditions
lymphomasolid tumor
Beyond the preview
Go deeper on NCT02800889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800889.